Research programme: prostate cancer therapeutic - Access Pharmaceuticals
Latest Information Update: 14 Jun 2014
At a glance
- Originator Access Pharmaceuticals; Unknown
- Developer Access Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 14 Jun 2014 No development reported for Prostate cancer in USA (PO)
- 27 Oct 2010 Early research in Prostate cancer in USA (PO)